Discovery of new symmetrical and asymmetrical nitrile-containing 1,4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies

References

• Chen S, Zhao Y, Liu S, et al. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance. Drug Resistance Updates 2022;61:100821–13.
   PubMed Web of Science ®Google Scholar
• Gupta N, Huang TT, Horibata S, Lee JM. Cell cycle checkpoints and beyond: exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer. Pharmacol Res 2022;178:106162–12.
   PubMed Web of Science ®Google Scholar
• Tu SM, Guo CC, Chow DSL, Zacharias NM. Stem cell theory of cancer: implications for drug resistance and chemosensitivity in cancer care. Cancers 2022;14:1548–11.
   PubMed Web of Science ®Google Scholar
• Li X, Li M, Huang M, et al. The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. Biomed Pharmacother 2022;150:113064–15.
   PubMed Web of Science ®Google Scholar
• Friedlaender A, Subbiah V, Russo A, et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol 2022;19:51–69.
   PubMed Web of Science ®Google Scholar
• Sitthideatphaiboon P, Teerapakpinyo C, Korphaisarn K, et al. Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer. Sci Rep 2022;12:13.
   PubMed Web of Science ®Google Scholar
• Hu L, Fan M, Shi S, et al. Dual target inhibitors based on EGFR: promising anticancer agents for the treatment of cancers. Eur J Med Chem 2017;227:1–25.
   Google Scholar
• Jiwacharoenchai N, Saruengkhanphasit R, Niwetmarin W, et al. Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the US National Cancer Institute database by in silico screening and bioactivity evaluation. Bioorg Med Chem Lett 2022;58:128524–5.
   PubMed Web of Science ®Google Scholar
• Sun W, Ma Z, Yan H. Biological evaluation of 4-aryl-1,4-dihydropyridines as VEGFR-2 kinase inhibitors. Russian J Gen Chem 2016;86:2891–9.
   Web of Science ®Google Scholar
• Deswal N, Shrivastava A, Summon Hossain M, et al. Design, synthesis, evaluation and molecular docking studies of novel triazole linked 1,4‐dihydropyridine‐isatin scaffolds as potent anticancer agents. ChemistrySelect 2021;6:717–25.
   Web of Science ®Google Scholar
• Mansour B, Bayoumi WA, El-Sayed MA, et al. In vitro cytotoxicity and docking study of novel symmetric and asymmetric dihydropyridines and pyridines as EGFR tyrosine kinase inhibitors. Chem Biol Drug Design 2022;10:121–135.
   Google Scholar
• Mohamed MF, Darweesh AF, Elwahy AH, Abdelhamid IA. Synthesis, characterization and antitumor activity of novel tetrapodal 1, 4-dihydropyridines: p53 induction, cell cycle arrest and low damage effect on normal cells induced by genotoxic factor H 2 O 2. RSC Adv 2016;6:40900–10.
   Web of Science ®Google Scholar
• Manna D, Bhuyan R, Ghosh R. Probing the mechanism of SIRT1 activation by a 1, 4-dihydropyridine. J Mol Modeling 2018;24:1–12.
   Web of Science ®Google Scholar
• Manna D, Bhuyan R, Saikh F, et al. Novel 1, 4-dihydropyridine induces apoptosis in human cancer cells through overexpression of Sirtuin1. Apoptosis 2018;23:532–53.
   PubMed Web of Science ®Google Scholar
• Sidhom PA, El-Bastawissy E, Salama AA, El-Moselhy TF. Revisiting ageless antiques; synthesis, biological evaluation, docking simulation and mechanistic insights of 1, 4-Dihydropyridines as anticancer agents. Bioorg Chem 2021;114:105054.
   PubMed Web of Science ®Google Scholar
• Cancer multidrug resistance. Nat Biotechnol 2000;18:18–20.
   Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Davudian S, et al. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 2017;7:339–48.
   PubMed Web of Science ®Google Scholar
• Choi YH, Yu A-M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Design 2014;20:793–807.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216–37.
   PubMed Web of Science ®Google Scholar
• Maki N, Hafkemeyer P, Dey S. Allosteric modulation of human P-glycoprotein: inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 2003;278:18132–9.
   PubMed Web of Science ®Google Scholar
• Zarrin A, Mehdipour AR, Miri R. Dihydropyridines and multidrug resistance: previous attempts, present state, and future trends. Chem Biol Drug Design 2010;76:369–81.
   PubMed Web of Science ®Google Scholar
• Ojima I, Bounaud PY, Oderda CF. Recent strategies for the treatment of multi-drug resistance in cancer cells. Exp Opin Ther Patents 1998;8:1587–98.
   Web of Science ®Google Scholar
• Sirisha K, Shekhar MC, Umasankar K, et al. Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors. Bioorg Med Chem 2011;19:3249–54.
   PubMedGoogle Scholar
• Sirisha K, Achaiah G, Reddy VM. Facile synthesis and antibacterial, antitubercular, and anticancer activities of novel 1, 4-dihydropyridines. Arch Pharm 2010;343:342–52.
   PubMed Web of Science ®Google Scholar
• Vijesh A, Isloor AM, Peethambar S, et al. Hantzsch reaction: synthesis and characterization of some new 1, 4-dihydropyridine derivatives as potent antimicrobial and antioxidant agents. Eur J Med Chem 2011;46:5591–7.
   PubMed Web of Science ®Google Scholar
• Perumal M, Sengodu P, Venkatesan S, et al. Polybenzimidazole-triphenylphosphene-catalyzed one-pot synthesis and evaluation of dihydropyridine derivative as antibiotics and antifungals. ChemistrySelect 2017;2:7489–96.
   Web of Science ®Google Scholar
• Mahinpour R, Moradi L, Zahraei Z, Pahlevanzadeh N. New synthetic method for the synthesis of 1, 4-dihydropyridine using aminated multiwalled carbon nanotubes as high efficient catalyst and investigation of their antimicrobial properties. J Saudi Chem Soc 2018;22:876–85.
   Web of Science ®Google Scholar
• Abu-Melha H. Synthesis, antibacterial and antifungal evaluation of novel 1,4-dihydropyridine derivatives. Spectrochim Acta A Mol Biomol Spectrosc 2013;113:115–22.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England J Med 2005;353:977–87.
   PubMed Web of Science ®Google Scholar
• Azevedo MM, Pina-Vaz C, Baltazar F. Microbes and cancer: friends or faux? Int J Mol Sci 2020;21:3115–23.
   PubMed Web of Science ®Google Scholar
• Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005;40:S246–S252.
   PubMed Web of Science ®Google Scholar
• Khatun S, Appidi T, Rengan AK. The role played by bacterial infections in the onset and metastasis of cancer. Curr Res Microb Sci 2021;2:100078–19.
   PubMedGoogle Scholar
• Elsland D, Neefjes J. Bacterial infections and cancer. EMBO Rep 2018;19:e46632.
   PubMed Web of Science ®Google Scholar
• Azap A, Bozkurt GY, Yüksel MK, et al. Secondary infections in cancer patients with febrile neutropenia. Turk J Hematol 2012;29:254–8.
   PubMed Web of Science ®Google Scholar
• Fleming FF, Yao L, Ravikumar P, et al. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. J Med Chem 2010;53:7902–17.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Li X, et al. Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies. RSC Med Chem 2021;12:1650–71.
   PubMedGoogle Scholar
• Berteotti A, Vacondio F, Lodola A, et al. Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. ACS Med Chem Lett 2014;5:501–5.
   PubMed Web of Science ®Google Scholar
• Fares S, Selim KB, Goda FE, et al. Design, synthesis, and analysis of antiproliferative and apoptosis-inducing activities of nitrile derivatives containing a benzofuran scaffold: EGFR inhibition assay and molecular modelling study. J Enzyme Inhibit Med Chem 2021;36:1488–99.
   PubMed Web of Science ®Google Scholar
• Nasser AA, Eissa IH, Oun MR, et al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Organic Biomol Chem 2020;18:7608–34.
   PubMed Web of Science ®Google Scholar
• Belal A, Abdel Gawad NM, Mehany ABM, et al. Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors. J Enzyme Inhibit Med Chem 2022;37:1884–902.
   PubMedGoogle Scholar
• Ahmed NM, Youns MM, Soltan MK, Said AM. Design, synthesis, molecular modeling and antitumor evaluation of novel indolyl-pyrimidine derivatives with EGFR inhibitory activity. Molecules 2021;26:1838.
   PubMedGoogle Scholar
• Suresh S, Das S, Waidha K, et al. Multi-component approach for synthesis of quinolinyl‐1, 4‐dihydropyridines, evaluation of cytotoxicity against MCF7 and molecular docking studies. ChemistrySelect 2020;5:10501–10.
   Web of Science ®Google Scholar
• Wang B, Zhao B, Chen ZS, et al. Exploration of 1, 2, 3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. Eur J Med Chem 2018;143:1535–42.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xu H, Ashby CR, Jr, et al. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev 2021;41:525–55.
   PubMed Web of Science ®Google Scholar
• Rashid M, Malik MY, Singh SK, et al. Bioavailability enhancement of poorly soluble drugs: the holy grail in pharma industry. Curr Pharm Design 2019;25:987–1020.
   PubMed Web of Science ®Google Scholar
• Wang B, Ma LY, Wang JQ, et al. Discovery of 5-cyano-6-phenylpyrimidin derivatives containing an acylurea moiety as orally bioavailable reversal agents against P-glycoprotein-mediated mutidrug resistance. J Med Chem 2018;61:5988–6001.
   PubMed Web of Science ®Google Scholar
• Ranjbar S, Edraki N, Firuzi O, et al. 5-Oxo-hexahydroquinoline: an attractive scaffold with diverse biological activities. Mol Div 2019;23:471–508.
   PubMed Web of Science ®Google Scholar
• Nkosi SM, Anand K, Anandakumar S, et al. Design, synthesis, anticancer, antimicrobial activities and molecular docking studies of novel quinoline bearing dihydropyridines. J Photochem Photobiol B Biol 2016;165:266–76.
   PubMed Web of Science ®Google Scholar
• Reddy GM, Camilo A. Jr, Biologically active dihydropyridines: an efficient green synthesis, antimicrobial properties, machine aided results and SARs. Sustain Chem Pharm 2020;17:100303–8.
   Web of Science ®Google Scholar
• Altalbawy FM. Synthesis and antimicrobial evaluation of some novel bis-α, β-unsaturated ketones, nicotinonitrile, 1, 2-dihydropyridine-3-carbonitrile, fused thieno [2, 3-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives. Int J Mol Sci 2013;14:2967–79.
   PubMed Web of Science ®Google Scholar
• Refat HM, Fadda A. Synthesis and antimicrobial activity of some novel hydrazide, benzochromenone, dihydropyridine, pyrrole, thiazole and thiophene derivatives. Eur J Med Chem 2013;70:419–26.
   PubMed Web of Science ®Google Scholar
• Ragab A, Fouad SA, Ali OAA, et al. Sulfaguanidine hybrid with some new pyridine-2-one derivatives: design, synthesis, and antimicrobial activity against multidrug-resistant bacteria as dual DNA gyrase and DHFR inhibitors. Antibiotics 2021;10:162–31.
   Google Scholar
• Murphy ST, Case HL, Ellsworth E, et al. The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents. Bioorg Med Chem Lett 2007;17:2150–5.
   PubMedGoogle Scholar
• Hantzsch A. Ueber die synthese pyridinartiger verbindungen aus acetessigäther und aldehydammoniak. Justus Liebigs Annalen Chem 1882;215:1–82.
   Google Scholar
• Iwanami M, Shibanuma T, Fujimoto M, et al. Synthesis of new water-soluble dihydropyridine vasodilators. Chem Pharm Bull 1979;27:1426–40.
   PubMed Web of Science ®Google Scholar
• Miri R, Javidnia K, Kebriaie-Zadeh A, et al. Synthesis and evaluation of pharmacological activities of 3,5‐dialkyl 1,4‐dihydro‐2,6‐dimethyl‐4‐nitroimidazole‐3,5‐pyridine dicarboxylates. Arch Der Pharm 2003;336:422–8.
   PubMed Web of Science ®Google Scholar
• Takimoto CH. Anticancer drug development at the US National Cancer Institute. Cancer Chemother Pharmacol 2003;52:29–33.
   Web of Science ®Google Scholar
• Monga M, Sausville EA. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia 2002;16:520–6.
   PubMed Web of Science ®Google Scholar
• Hohla F, Buchholz S, Schally AV, et al. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Lett 2010;294:35–42.
   PubMed Web of Science ®Google Scholar
• Hammoud MM, Nageeb AS, Morsi M, et al. Design, synthesis, biological evaluation, and SAR studies of novel cyclopentaquinoline derivatives as DNA intercalators, topoisomerase II inhibitors, and apoptotic inducers. New J Chem 2022;46:11422–36.
   Web of Science ®Google Scholar
• Ren YJ, Wang ZC, Zhang X, et al. EGFR/HER-2 inhibitors: synthesis, biological evaluation and 3D-QSAR analysis of dihydropyridine-containing thiazolinone derivatives. RSC Adv 2015;5:21445–54.
   Web of Science ®Google Scholar
• Abdel-Aziz AA-M, El-Azab AS, AlSaif NA, et al. Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study. J Enzyme Inhib Med Chem 2021;36:1520–38.
   Web of Science ®Google Scholar
• Pfeffer CM, Singh AT. Apoptosis: a target for anticancer therapy. Int J Mol Sci 2018;19:448–57.
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51.
   PubMed Web of Science ®Google Scholar
• Abdelrahman MA, Eldehna WM, Nocentini A, et al. Novel diamide-based benzenesulfonamides as selective carbonic anhydrase IX inhibitors endowed with antitumor activity: synthesis, biological evaluation and in silico insights. Int J Mol Sci 2019;20:2484–99.
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 2017;17:93–115.
   PubMed Web of Science ®Google Scholar
• Shaaban S, Negm A, Sobh MA, Wessjohann LA. Organoselenocyanates and symmetrical diselenides redox modulators: design, synthesis and biological evaluation. Eur J Med Chem 2015;97:190–201.
   PubMed Web of Science ®Google Scholar
• Ahamed A, Arif IA, Mateen M, et al. Antimicrobial, anticoagulant, and cytotoxic evaluation of multidrug resistance of new 1,4-dihydropyridine derivatives. Saudi J Biol Sci 2018;25:1227–35.
   PubMed Web of Science ®Google Scholar
• Mollazadeh S, Sahebkar A, Kalalinia F, et al. Synthesis, in silico and in vitro studies of new 1,4-dihydropiridine derivatives for antitumor and P-glycoprotein inhibitory activity. Bioorg Chem 2019;91:103156–66.
   PubMed Web of Science ®Google Scholar
• Aziz MW, Kamal AM, Mohamed KO, Elgendy AA. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines. Bioorg Med Chem Lett 2021;41:127987–97.
   PubMed Web of Science ®Google Scholar
• Zou M, Li J, Jin B, et al. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg Chem 2021;114:105200–10.
   PubMed Web of Science ®Google Scholar
• Zhang D, Gong H, Meng F. Recent advances in BTK Inhibitors for the treatment of inflammatory and autoimmune diseases. Molecules 2021;26:4907–41.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Seto M, Banno H, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo [3,2-d] pyrimidine scaffold. J Med Chem 2011;54:8030–50.
   PubMed Web of Science ®Google Scholar
• Mao C, Zhou M, Uckun FM. Crystal structure of Bruton’s tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem 2001;276:41435–43.
   PubMed Web of Science ®Google Scholar
• Sultan MM, Denny RA, Unwalla R, et al. Millisecond dynamics of BTK reveal kinome-wide conformational plasticity within the apo kinase domain. Sci Rep 2017;7:15604–15.
   PubMed Web of Science ®Google Scholar
• El-Moselhy T. Synthesis of 1,4-dihydropyridine Hantzsch esters as potential calcium channel blockers. Alexandria J Pharm Sci 2002;16:35–9.
   Google Scholar
• Bazargan L, Fouladdel S, Shafiee A, et al. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro. Cell Biol Toxicol 2008;24:165–74.
   PubMed Web of Science ®Google Scholar
• Cindric M, Cipak ANA, Serly J, et al. Reversal of multidrug resistance in murine lymphoma cells by amphiphilic dihydropyridine antioxidant derivative. Anticancer Res 2010;30:4063–94069.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Ibrahim HS, et al. Novel [(3-indolylmethylene) hydrazono] indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in vitro biological evaluation. J Enzyme Inhibit Med Chem 2018;33:686–700.
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Abdelmoniem AM, Elwahy AH, Abdelhamid IA. DNA fragmentation, cell cycle arrest, and docking study of novel bis spiro-cyclic 2-oxindole of pyrimido [4,5-b] quinoline-4, 6-dione derivatives against breast carcinoma. Curr Cancer Drug Targets 2018;18:372–81.
   PubMed Web of Science ®Google Scholar
• Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 2008;8:1555–72.
   PubMed Web of Science ®Google Scholar